This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Dec 9, 2024
•
9 min read
Novo Holdings' Catalent acquisition gets go-ahead from EU regulators, Teva & Takeda divest generics joint venture to PE firm, bluebird bio touts positive long-term sickle cell disease gene therapy data, National Resilience layoffs + 24 more stories
Dec 6, 2024
8 min read
Atlas Venture closes $450M Fund XIV focused on biotech, Protara Therapeutics positive Ph2 cell therapy data launches stock upward, Nuvig Therapeutics $161M Series B for non-immune system suppressing autoimmune therapies, Eli Lilly & Amgen both announce $1B+ facility builds + 20 more stories
Dec 5, 2024
11 min read
Eli Lilly's Zepbound beats Novo Nordisk's Wegovy in obesity head-to-head, Merus' mAb Bizengri nabs pancreatic and lung cancer approvals, Antag Therapeutics joins the obesity race with an $84M Series A, Novo Nordisk buys Novavax manufacturing site + 34 more stories
Dec 4, 2024
10 min read
Maze Therapeutics $115M Series D fuels kidney disease ambitions, Gilead buys ADC discovery option from Tubulis, Janux T-cell engager Ph1b dose escalation data launches stock 50%, GSK's hep B vaccine hopeful sputters in Ph1/2, insult to injury as Applied Therapeutics handed FDA warning letter + 29 more stories
Dec 3, 2024
Novartis signs up to $3B deal for PTC Huntington's asset, Senti Bio's stock launches 400%+ on early Ph1 CAR-NK data, Sanofi earmarks €1B for Beijing-based insulin manufacturing plant, KisoJi lands $41M in equity fuel for TROP2-targeting solid tumor clinical asset + 25 more stories
Dec 2, 2024
bluebird bio's Skysona blood cancer risk comes under FDA scrutiny, BeiGene lands a first-line Tevimbra (PD-1) approval, PTC Therapeutics to sell their PRV for $150M, BMS joins the 340B lawsuit party + 36 more stories
Nov 27, 2024
Roche paying a pretty penny for Poseida's allogeneic cell therapy ambitions, Amgen's MariTide weight loss Ph2 data isn't enough for investors, Cradle Bio $73M Series B for AI-driven protein design, Roche’s anti-TIGIT mAb misses in lung cancer Ph3 + 26 more stories
Nov 26, 2024
Cassava's much-controversial Alzheimer's hopeful flunks in Ph3, Alnylam whips out the priority review voucher for cardiomyopathy asset, Adcendo's ADC hopes get $135M injection, AstraZeneca touts Truqap prostrate cancer subtype Ph3 win + 27 more stories
Nov 25, 2024
BridgeBio's Attruby lands FDA approval, Roche's Vabysmo touts potentially lucrative (in Asia) Ph3b/4 data in polypoidal choroidal vasculopathy, Nabla Bio's coming for the AI-designed protein crown, ALS hopeful Seelos Therapeutics files for bankruptcy + 21 more stories
Nov 22, 2024
Novartis buys gene therapy's Kate Therapeutics for up to $1.1B, Enveda snags $130M Series C on AI-analyzed plant-derived molecules, Pharma ads might go bye-bye if RFK Jr. has his way, CBER's Peter Marks sees vaccine debates as not "a bad thing", Pyxis Oncology’s PYX-201 Ph1 data doesn't inspire investor confidence + 25 more stories
Nov 21, 2024
Pfizer signs drug discovery partnerships with two Flagship portfolio companies, Samsung Biologics scores a bunch of European manufacturing deal, Novartis and Vyriad partner on in-vivo CAR-T generation, Sage Therapeutics' potentially fatal Ph2 blow, RFK Jr. wants to "blow...up" the FDA + 29 more stories
Nov 20, 2024
Dr. Oz to lead Medicare & Medicaid, “fail fast” biotech venture foundry Jupiter Bioventures launches with $70M, BeiGene (soon to BeOne Medicines) settles Brukinsa generic spat with MSN Pharmaceuticals, AstraZeneca’s Andexxa FDA adcom chances not looking good after “major safety findings” + 31 more stories
